Rapid communicationCan finasteride reverse the progress of benign prostatic hyperplasia? a two-year placebo-controlled study
References (19)
- et al.
The incidence of benign prostatic obstruction
J Urol
(1968) What makes prostate grow
J Urol
(1953)- et al.
The conversion of testosterone to 5alpha-androstane-17beta-ol-3 one by rat prostate in vivo and in vitro
J Biol Chem
(1968) Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia
Urology
(1994)- et al.
Maximum urinary flow rate by uroflowmetry: automatic or visual interpretation
J Urol
(1993) - et al.
Accuracy of portable ultrasound scanning in the measurement of residual urine volume
J Urol
(1994) - et al.
Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate
J Urol
(1995) Benign prostatic hyperplasia: medical and minimally invasive treatment options
N Engl J Med
(1995)Benign prostatic hyperplasia: antecedents and natural history
Epidemiol Rev
(1992)
Cited by (146)
Post-finasteride syndrome: a surmountable challenge for clinicians
2020, Fertility and SterilityCitation Excerpt :Although the concerns regarding finasteride adverse effects led the NIH to add PFS to its Genetic and Rare Disease Information Center, PFS has yet to be recognized by the medical community, even though several patients do present with very severe, peculiar and classical symptoms. It is distressing that many clinicians and key opinion leaders from various clinical disciplines continue to dispute and dismiss any notion that PFS is real (64–66, 82, 85, 87–89, 93, 119, 120, 132, 134, 135, 139,141, 143, 144, 150, 153, 160, 162, 167, 171, 173, 174, 181, 185, 190–200). Most disturbing, however, is clinicians labeling of patients with PFS as unstable, psychotic or delusional (65, 66).
5-Alpha-Reductase Inhibitors and Combination Therapy
2016, Urologic Clinics of North AmericaCitation Excerpt :Subjects who switched from PBO to FIN during extension showed at study end the same AUR reduction and prostate surgery incidence as the continuous FIN arm.17 Various other clinical trials compared FIN 5 mg versus PBO and reported similar outcomes, which means a reduction of prostate size by −15% to −21%, an IPSS (or similar score) reduction by −13% to −38%, and an increase of Qmax by 1.6 to 2.2 mL/s.18–22 In all studies, these effects were measurable after 6 to 12 months. Meta-analysis revealed that the difference in improvement between FIN and PBO becomes significant when the prostate volume is greater than 40 mL at baseline.23
Assessment and management of male lower urinary tract symptoms (LUTS)
2016, International Journal of SurgeryCitation Excerpt :5-ARIs reduce the prostate size by about 18–28% and PSA by about 50% [57]. Clinical effects are generally seen several months after initiation of treatment [58]. The adverse effects of 5-ARIs are reduced libido, erectile dysfunction and, less frequently, ejaculation disorders (retrograde ejaculation, ejaculation failure, or decreased semen volume) [57].
Guidelines for the management of benign prostatic hyperplasia. Colombian Urological Society 2014
2015, Urologia ColombianaAcute Urinary Retention Rates in the General Male Population and in Adult Men with Lower Urinary Tract Symptoms Participating in Pharmacotherapy Trials: A Literature Review
2015, UrologyCitation Excerpt :AUR rates in 2 non-placebo controlled studies were variable, occurring in 11 (1.3%; 13.5 per 1000 man-years) and 374 (14.7%; 147.0 per 1000 man-years) patients.24,25 In a post hoc analysis of the 2-year SCARP study (n = 707 LUTS/BPH patients), AUR was reported in 4 men on finasteride (1.1%; 5.7 per 1000 man-years) vs 15 on placebo (4.2%; 21.2 per 1000 man-years; P = .02)30; in the 2-year PROWESS study in 3168 men with LUTS/BPH, AUR was reported in 15 men on finasteride 5 mg/day (1.0%; 4.8 per 1000 man-years) vs 37 on placebo (2.5%; 11.6 per 1000 man-years; RRR 57%).29 Similar reductions were reported in the 4-year PLESS study in 3040 men with LUTS/BPH (42 [2.8%; 6.9 per 1000 man-years] on finasteride vs 99 [6.6%; 16.3 per 1000 man-years] on placebo; RRR 57%; P <.001), and sustained in a 2-year open extension study31,32 and in the MTOPS study: 6 events with finasteride (0.8%; 2 per 1000 man-years) vs 18 with placebo (2.4%; 6.1 per 1000 man-years) at 4 years; RRR 68%; P = .009.14
- *
Members of the Scandinavian BPH Study Group are Denmark: J.T. Andersen, A. Bodker, O. Vedel, Hvidovre Hospital; J. Nordling, A.L. Poulsen, J. Schou, Herlev Sygehus; V. Hvidt, J.B. Hansen, Bispebjerg Hospital; H.H. Meyhoff, J. Eldrup, D. Hartwell, Hillerod Sygehus; H. Colstrup; P. Lyngdorf, Gentofte Amts Sygehus; A. Holm Nielsen, Esbjerg Centralsygehus; E. Larsen, Naestved Centralsygehus; H. Wolf, Skejby Sygehus; S. Walter, E.H. Larsen, Aalborg Sygehus; E. Thybo, S. Mommsen, K.E. Brok, Odense Sygehus; L. Palm, Roskilde Sygehus; H. Genster, M. Andersen, Sonderborg Sygehus.